Literature DB >> 14521408

Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists.

Kristina E Furse1, Terry P Lybrand.   

Abstract

Molecular modeling methods have been used to construct three-dimensional models for agonist and antagonist complexes with beta-adrenergic receptors. The recent rhodopsin crystal structure was used as a template in standard homology modeling methods. The rhodopsin-based homology models were assessed for agreement with experimental results for beta-adrenergic receptors, and compared with receptor models developed using de novo modeling techniques. While the de novo and homology-derived receptor models are generally quite similar, there are some localized structural differences that impact the putative ligand-binding site significantly. The de novo receptor models appear to provide much better agreement with experimental data, particularly for receptor complexes with agonist ligands. The de novo receptor models also yield some interesting and testable hypotheses for the structural basis of beta-adrenergic receptor subtype ligand selectivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521408     DOI: 10.1021/jm0301437

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?

Authors:  Hao Tang; Xiang Simon Wang; Jui-Hua Hsieh; Alexander Tropsha
Journal:  Proteins       Date:  2012-03-13

2.  Insights into the binding modes of human β₃-adrenergic receptor agonists with ligand-based and receptor-based methods.

Authors:  Fangfang Jin; Chunhua Lu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  Mol Divers       Date:  2011-03-20       Impact factor: 2.943

3.  Purine receptors: GPCR structure and agonist design.

Authors:  Kenneth A Jacobson; Soo-Kyung Kim; Stefano Costanzi; Zhan-Guo Gao
Journal:  Mol Interv       Date:  2004-12

4.  Modeling and active site refinement for G protein-coupled receptors: application to the beta-2 adrenergic receptor.

Authors:  Stanley R Krystek; S Roy Kimura; Andrew J Tebben
Journal:  J Comput Aided Mol Des       Date:  2006-10-13       Impact factor: 3.686

5.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

Authors:  Vadim Cherezov; Daniel M Rosenbaum; Michael A Hanson; Søren G F Rasmussen; Foon Sun Thian; Tong Sun Kobilka; Hee-Jung Choi; Peter Kuhn; William I Weis; Brian K Kobilka; Raymond C Stevens
Journal:  Science       Date:  2007-10-25       Impact factor: 47.728

6.  Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonists.

Authors:  P Senthil Kumar; Prasad V Bharatam
Journal:  Med Chem Res       Date:  2009-10-31       Impact factor: 1.965

7.  Role of group-conserved residues in the helical core of beta2-adrenergic receptor.

Authors:  Prashen Chelikani; Viktor Hornak; Markus Eilers; Phillip J Reeves; Steven O Smith; Uttam L RajBhandary; H Gobind Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-16       Impact factor: 11.205

8.  Characterization of beta3-adrenergic receptor: determination of pharmacophore and 3D QSAR model for beta3 adrenergic receptor agonism.

Authors:  Philip Prathipati; Anil K Saxena
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

9.  Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.

Authors:  Krzysztof Jozwiak; Anthony Yiu-Ho Woo; Mary J Tanga; Lawrence Toll; Lucita Jimenez; Joseph A Kozocas; Anita Plazinska; Rui-Ping Xiao; Irving W Wainer
Journal:  Bioorg Med Chem       Date:  2009-12-06       Impact factor: 3.641

10.  Computational study on the different ligands induced conformation change of β2 adrenergic receptor-Gs protein complex.

Authors:  Qifeng Bai; Yang Zhang; Yihe Ban; Huanxiang Liu; Xiaojun Yao
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.